SGLT2 Inhibitors in Diabetic CKD: Metabolic Wins, Neutral Surrogates

This meta-analysis quantifies short- to medium-term surrogate, metabolic, and safety effects of SGLT2 inhibitors specifically in diabetic CKD, reinforcing a favorable risk profile while cautioning about volume depletion.

SGLT2 inhibitorscanagliflozindapagliflozinempagliflozinsotagliflozinbexagliflozindiabetic chronic kidney diseasetype 2 diabetesnephrologymeta-analysiseGFRalbuminuriavolume depletion Nephrology / Renal Pharmacy

Background Information

SGLT2 inhibitors offer metabolic benefits but risk volume depletion in diabetic CKD.

Chronic kidney disease (CKD) in diabetes is linked with high cardiovascular risks. Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer potential renoprotective and metabolic benefits. SGLT2 inhibitors reduced glycated hemoglobin by 0.40%, body weight by 1.36 kg, and systolic blood pressure by 2.98 mm Hg without significant changes in estimated glomerular filtration rate (eGFR) or urinary albumin-to-creatinine ratio (UACR). They increased the risk of volume depletion-related events. SGLT2 inhibitors offer metabolic benefits in diabetic CKD, but clinical use should consider potential volume depletion risks. Long-term studies indicate cardiorenal protection. SGLT2 inhibitors provide glycemic and hemodynamic benefits in diabetic CKD, with manageable safety concerns.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Shi X, Fu K, Hu M, Li R, Li H, Xu S

Citation: Shi X, Fu K, Hu M, et al. Renoprotective effects and safety of sodium-glucose cotransporter 2 inhibitors in diabetic chronic kidney disease: A systematic review and meta-analysis. Medicine. 2026;105(40):e50957. doi:10.1097/MD.0000000000050957

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →